Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-CHRNB1 Recombinant Antibody (N0675) (CBMAB-N0675-WJ)


See all CHRNB1 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
N0675
Antibody Isotype
IgG2b, κ
Application
ELISA, IF, WB, IP

Basic Information

Immunogen
Amino acids 356-456 mapping near the C-terminus of AChRβ1 of human.
Host Species
Mouse
Specificity
Human
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal Antibody
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.
ApplicationNote
WB1:100-1:1,000
IP1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)1:50-1:500
ELISA1:100-1:1,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, 0.1% gelatin
Preservative
< 0.1% sodium azide
Concentration
0.2 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Cholinergic Receptor Nicotinic Beta 1 Subunit
Introduction
The muscle acetylcholine receptor is composed of five subunits: two alpha subunits and one beta, one gamma, and one delta subunit. This gene encodes the beta subunit of the acetylcholine receptor. The acetylcholine receptor changes conformation upon acetylcholine binding leading to the opening of an ion-conducting channel across the plasma membrane. Mutations in this gene are associated with slow-channel congenital myasthenic syndrome. [provided by RefSeq, Jul 2008]
Entrez Gene ID
1140
UniProt ID
P11230
Alternative Names
Cholinergic Receptor Nicotinic Beta 1 Subunit; Cholinergic Receptor, Nicotinic, Beta Polypeptide 1 (Muscle); Acetylcholine Receptor, Nicotinic, Beta 1 (Muscle); Cholinergic Receptor, Nicotinic, Beta 1 (Muscle); Cholinergic Receptor, Nicotinic Beta 1; CHRNB; ACHRB;
Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Biological Process
Behavioral response to nicotine Source: UniProtKB
Cation transport Source: UniProtKB
Chemical synaptic transmission Source: GO_Central
Ion transmembrane transport Source: GO_Central
Muscle contraction Source: UniProtKB
Muscle fiber development Source: UniProtKB
Nervous system process Source: UniProtKB
Neuromuscular synaptic transmission Source: UniProtKB
Postsynaptic membrane organization Source: UniProtKB
Regulation of membrane potential Source: UniProtKB
Signal transduction Source: UniProtKB
Skeletal muscle contraction Source: Ensembl
Synaptic transmission, cholinergic Source: UniProtKB
Cellular Location
Postsynaptic cell membrane; Cell membrane
Involvement in disease
Myasthenic syndrome, congenital, 2A, slow-channel (CMS2A): A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane.
Myasthenic syndrome, congenital, 2C, associated with acetylcholine receptor deficiency (CMS2C): A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2C is an autosomal recessive disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current. CMS2C is clinically characterized by early-onset muscle weakness with variable severity.
Topology
Extracellular: 24-244
Helical: 245-269
Helical: 277-295
Helical: 311-332
Cytoplasmic: 333-469
Helical: 470-488
More Infomation
Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-CHRNB1 Recombinant Antibody (N0675)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry